CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia

Experimental Hematology

Volumn 38, Issue 3, 2010, Pages 165-173

  Citores, Maria Jesus ^a   Castejon, Raquel ^a   Villarreal, Mercedes ^a   Rosado, Silvia ^a   Garcia Marco, Jose Antonio ^a   Vargas, Juan Antonio ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CLADRIBINE; FLUDARABINE;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AUTOIMMUNITY; CD40 LIGAND; CELLS, CULTURED; CLADRIBINE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; VIDARABINE;

EID: 76749120373     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.12.001     Document Type: Article

References (38)

1. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 123 (2003) 380-388
2. Granziero L., Ghia P., Circosta P., et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97 (2001) 2777-2783
3. Keating M.J., Kantarjian H., O'Brien S., et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9 (1991) 44-49
4. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1750-1757
5. Abbott B.L. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist 11 (2006) 21-30
6. Diehl L.F., and Ketchum L.H. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 25 (1998) 80-97
7. Hamblin T.J. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 33 (2006) 230-239
8. van Kooten C., and Banchereau J. CD40-CD40 ligand. J Leukoc Biol 67 (2000) 2-17
9. Datta S.K., and Kalled S.L. CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum 40 (1997) 1735-1745
10. Citores M.J., Rua-Figueroa I., Rodriguez-Gallego C., et al. The dinucleotide repeat polymorphism in the 3'UTR of the CD154 gene has a functional role on protein expression and is associated with systemic lupus erythematosus. Ann Rheum Dis 63 (2004) 310-317
11. Funakoshi S., Longo D.L., Beckwith M., et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83 (1994) 2787-2794
12. Ghia P., Boussiotis V.A., Schultze J.L., et al. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood 91 (1998) 244-251
13. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
14. Crespo M., Bosch F., Villamor N., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348 (2003) 1764-1775
15. Grammer A.C., Bergman M.C., Miura Y., Fujita K., Davis L.S., and Lipsky P.E. The CD40 ligand expressed by human B cells costimulates B cell responses. J Immunol 154 (1995) 4996-5010
16. Robak T., Blonski J.Z., Kasznicki M., et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia-updated results of the multicentre study of 378 patients. Br J Haematol 108 (2000) 357-368
17. Dohner H., Fischer K., Bentz M., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85 (1995) 1580-1589
18. Turgut B., Vural O., Pala F.S., et al. 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis. Leuk Lymphoma 48 (2007) 311-320
19. Gricks C.S., Zahrieh D., Zauls A.J., et al. Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. Blood 104 (2004) 4002-4009
20. Romano M.F., Lamberti A., Tassone P., et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 92 (1998) 990-995
21. Kitada S., Zapata J.M., Andreeff M., and Reed J.C. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 106 (1999) 995-1004
22. Hallaert D.Y., Jaspers A., van Noesel C.J., van Oers M.H., Kater A.P., and Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 112 (2008) 5141-5149
23. Grdisa M. Influence of CD40 ligation on survival and apoptosis of B-CLL cells in vitro. Leuk Res 27 (2003) 951-956
24. de Totero D., Tazzari P.L., Capaia M., et al. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation. Haematologica 88 (2003) 148-158
25. Cantwell M., Hua T., Pappas J., and Kipps T.J. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med 3 (1997) 984-989
26. Schattner E.J., Mascarenhas J., Reyfman I., et al. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity. Blood 91 (1998) 2689-2697
27. Younes A., Snell V., Consoli U., et al. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br J Haematol 100 (1998) 135-141
28. Bosanquet A.G., Johnson S.A., and Richards S.M. Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. Br J Haematol 106 (1999) 71-77
29. Castejon R., Yebra M., Citores M.J., Villarreal M., Garcia-Marco J.A., and Vargas J.A. Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 50 (2009) 593-603
30. Barcellini W., Capalbo S., Agostinelli R.M., et al. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica 91 (2006) 1689-1692
31. Mauro F.R., Foa R., Cerretti R., et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 95 (2000) 2786-2792
32. Dazzi F., D'Andrea E., Biasi G., et al. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin Immunol Immunopathol 75 (1995) 26-32
33. Van den Hove L.E., Van Gool S.W., Vandenberghe P., et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 11 (1997) 572-580
34. Hall A.M., Vickers M.A., McLeod E., and Barker R.N. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 105 (2005) 2007-2015
35. Damle R.N., Wasil T., Fais F., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94 (1999) 1840-1847
36. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., and Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 (1999) 1848-1854
37. Aleskog A., Tobin G., Laurell A., et al. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia. Eur J Haematol 73 (2004) 407-411
38. Del Poeta G., Maurillo L., Venditti A., et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 98 (2001) 2633-2639